Skip to content

Progesterone Supplementation on Women Having Low Progesterone Levels on Transfer Day

Effectiveness of Progesterone Supplementation for Women Having Low Progesterone Levels on the Day of Frozen Embryo Transfer

Status
UNKNOWN
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04897269
Enrollment
824
Registered
2021-05-21
Start date
2021-05-20
Completion date
2024-06-20
Last updated
2023-12-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Assisted Reproductive Technology

Keywords

low progesterone levels, progesterone supplementation, clinical pregnancy

Brief summary

The main objective of this study is to compare clinical pregnancy rates between two groups of women who have progesterone levels below 10 ng/mL on the day of frozen embryo transfer: group 1 (vaginal micronized progesterone supplemented with progesterone intramuscular 50 mg per day) and group 2 (vaginal micronized progesterone with no supplementation)

Detailed description

Trial Design: Single center, longitudinal, randomized, interventional, controlled, pharmacological study, enrolling women attending clinical Centers of medically assisted reproduction (ART). The study protocol consists in the record of all the diagnostic and clinical outcome parameters, according to clinical practice, for the following patient cohorts: * The patients who are undergoing frozen embryo transfers with blastocyst or cleavage stage embryos and have progesterone levels below 10 ng/mL on the day of embryo transfer * Study groups * Group supplemented with progesterone intramuscular 50 mg per day until the day of beta-hcg testing (Intervention group); * Group with no supplementation (Control group). * Endometrial cycle is started with estradiol valerate dose of 4 mg to 8 mg per day, the patients then are appointed to have ultrasound scan of their endometrium every 3 to 7 days and the dose of estradiol may be increased to 16 mg per day maximum depends on the thickness of endometrium; when their endometrium reach 8 mm or higher and duration of endometrial preparation is ≥ 12 days, the embryo transfer will be planned and transvaginal progesterone are prescribed according to the day of transfer. * If this is the first cycle of embryo transfer and she is \< 35 years of age, 1 grade 1 embryo is transferred, otherwise 2 embryos are transferred. * In the morning of embryo-transferred day, all patients will have their blood tested for progesterone levels, if their levels below 10 ng/mL, they will be recruited into the study and randomized into two groups. * In the study group, the patients will be prescribed with intramuscular progesterone supplemetation 50 mg + 800mg vaginal micronized progesterone per day for 14 days, until the day of beta-hcg testing. * In the control group, the patients will continue their regular medications (800mg vaginal micronized progesterone per day) until the day of beta-hcg testing without any progesterone supplementation. * If the beta-hcg test is positive, the patients will be continued their prescriptions depending on study or control group as mentioned above till 7 weeks of pregnancy when the fetal heart can be confirmed, then the patients will be followed up till 11 - 12 weeks of pregnancy

Interventions

This procedure is to add more progesterone on those who have low progesterone levels on the day of embryo transfer

Sponsors

Tu Du Hospital
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Intervention model description

Patients who have progesterone levels below 10 ng/mL on the day of embryo transfer will be randomized into 2 groups: 1. Those who will be supplemented with intramuscular progesterone 50mg per day till day of beta-hcg testing 2. Those who will continue their regular medications

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

* Patients undergone ART with frozen embryo transfer, blastocyst or cleavaged stage embryo transfer, from 18-45 years of age * Normal BMI * HRT for Endometrial preparation in FET cycles

Exclusion criteria

* Oocyte donor cycles * Surrogacy * IVM * PGT * Abnormal Uterine (firbroids 0 -\> 3 according to FIGO classification, polyp, adenomyosis, congenital malformation) * Uterus fibroids type 4,5 (Figo classification) \> 4cm * History of recurrent implantation failure * Endometrial thickness \<7mm on the day of ET * Cesarean scar defect (isthmocele)

Design outcomes

Primary

MeasureTime frameDescription
Ongoing pregnancy rateweek 11 - 14 of pregnancydefined as the pregnancy completed 11 - 14 weeks of gestation and having vital fetus

Secondary

MeasureTime frameDescription
implantation rate3 weeks after embryo transferthe percentage of embryos which successfully undergo implantation compared to the number of embryos transferred in a given period
Pregnancy rate2 weeks after embryo transferbeta-hCG test is positive
clinical pregnancy rate3 weeks after embryo transferpregnancy when fetal heart can be confirmed

Countries

Vietnam

Contacts

Primary ContactChau TM Le, PhD
dr.lethiminhchau@gmail.com+84908429006
Backup ContactAnh Q Nguyen, Master
dr.anhquocnguyen@gmail.com+84976137562

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 13, 2026